The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: Comments on the article by Soderlin et al

Scandinavian Journal of Rheumatology

Volumn 41, Issue 5, 2012, Pages 411-412

  Park, S J ^a   Shin, J I ^a,b  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE ACTIVITY; DRUG BIOAVAILABILITY; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SMOKING; SMOKING CESSATION; SOCIAL STATUS; SURVIVAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867277925     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.698394     Document Type: Letter

References (8)

1. Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012;41:1-9.
2. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006;45:734-40.
3. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010;62:1128-43.
4. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-Alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65.
5. Shin JI, Park SJ, Kim JH. Apossible role of leptin-Associated increase in soluble interleukin-2 receptor diminishing a clinical response to infliximab in rheumatoid arthritis: comment on the article by Klaasen et al. Arthritis Rheum 2011;63:2833-4.
6. Kuuliala A, Leirisalo-Repo M, Mottonen T, Hannonen P, Nissila M, Kautiainen H, et al. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug. Clin Exp Rheumatol 2005;23:243-6.
7. Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. Ann Rheum Dis 2006;65:26-9.
8. Tollerud DJ, Kurman CC, Nelson DL, Brown LM, Maloney EM, Blattner WA. Racial variation in serum-soluble interleukin-2 receptor levels: a population-based study of healthy smokers and nonsmokers. Clin Immunol Immunopathol 1994; 70:274-9.